Analysts Offer Insights on Healthcare Companies: Nivalis Therapeutics (NASDAQ: NVLS) and HTG Molecular Diagnostics (NASDAQ: HTGM)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nivalis Therapeutics (NASDAQ: NVLS) and HTG Molecular Diagnostics (NASDAQ: HTGM).

Nivalis Therapeutics (NASDAQ: NVLS)

Cowen & Co. analyst Phil Nadeau reiterated a Hold rating on Nivalis Therapeutics (NASDAQ: NVLS) yesterday. The company’s shares opened today at $2.68.

Nadeau said:

“This evening Nivalis and Alpine Immune Sciences announced an agreement to merge.”

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 5.2% and a 48.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Nivalis Therapeutics has an analyst consensus of Hold.

HTG Molecular Diagnostics (NASDAQ: HTGM)

In a report released yesterday, Mark Massaro from Canaccord Genuity reiterated a Buy rating on HTG Molecular Diagnostics (NASDAQ: HTGM), with a price target of $6.50. The company’s shares opened today at $5.71.

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 10.2% and a 61.5% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc, Quest Diagnostics Inc, and Orasure Technologies.

HTG Molecular Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $6.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.